NEUREN PHARMACEUTICALS LIMITED



RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING Monday, 29 June, 2020

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RE-ELECTION OF TREVOR SCOTT AS A DIRECTOR	N	30,710,386 98.60%	214,293 0.69%	221,872 0.71%	36,868	31,515,424 99.32%	214,293 0.68%	36,868	Carried
2	AUTHORISATION TO FIX AUDITOR FEES AND EXPENSES	N	30,853,068 99.09%	110,750 0.36%	172,711 0.55%	46,890	31,608,945 99.65%	110,750 0.35%	46,890	Carried
3	APPROVAL TO ISSUE LOAN FUNDED SHARES TO JON PILCHER	Ν	28,051,407 90.07%	2,957,441 9.50%	134,307 0.43%	40,264	28,663,875 90.35%	3,062,446 9.65%	40,264	Carried
4	APPROVAL TO ISSUE LOAN FUNDED SHARES TO JAMES SHAW	Ν	28,032,493 90.07%	2,957,691 9.50%	134,307 0.43%	39,450	28,644,961 90.34%	3,062,696 9.66%	39,450	Carried
5	APPROVAL TO ISSUE LOAN FUNDED SHARES TO CLIVE BLOWER	N	28,050,407 90.04%	2,907,441 9.33%	197,121 0.63%	28,450	28,725,689 90.51%	3,012,446 9.49%	28,450	Carried
6	APPROVAL OF ADDITIONAL 10% PLACEMENT CAPACITY UNDER LISTING RULE 7.1A	N	29,297,101 94.72%	1,409,977 4.56%	223,436 0.72%	252,905	29,997,094 95.19%	1,516,586 4.81%	252,905	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item